Summary:  Major shareholder announcement for Genmab A/S.                       


Copenhagen, Denmark; November 24, 2009 - Genmab A/S (OMX: GEN) announces
under  
reference to Section 29 of the Danish Securities Trading Act that
GenPharm      
International, Inc. has informed us that their ownership in
Genmab A/S as of    
November 24, 2009 consists of 2,243,294 shares, which is
4.99% of the total     
shares, thereby falling below the 5 percent threshold.
                         

About Genmab A/S                                  
                             
Genmab is a leading international biotechnology
company focused on developing   
fully human antibody therapeutics for the
potential treatment of cancer.        
Genmab's world class discovery and
development teams are using cutting-edge     
technology to create and develop
products to address unmet medical needs.  Our  
primary goal is to improve the
lives of patients who are in urgent need of new  
treatment options.  For more
information on Genmab's products and technology,   
visit www.genmab.com.     
                                                     

This Stock Exchange
Release contains forward looking statements. The words      
“believe”,
“expect”, “anticipate”, “intend” and “plan” and similar expressions  
identify
forward looking statements. Actual results or performance may differ  

materially from any future results or performance expressed or implied by
such  
statements. The important factors that could cause our actual results
or        
performance to differ materially include, among others, risks
associated with   
product discovery and development, uncertainties related to
the outcome and     
conduct of clinical trials including unforeseen safety
issues, uncertainties    
related to product manufacturing, the lack of market
acceptance of our products,
our inability to manage growth, the competitive
environment in relation to our  
business area and markets, our inability to
attract and retain suitably         
qualified personnel, the unenforceability
or lack of protection of our patents  
and proprietary rights, our
relationships with affiliated entities, changes and 
developments in
technology which may render our products obsolete, and other    
factors. For
a further discussion of these risks, please refer to the section   
“Risk
Management” in Genmab's Annual Report, which is available on             

www.genmab.com.  Genmab does not undertake any obligation to update or revise
  
forward looking statements in this Stock Exchange Release nor to confirm
such   
statements in relation to actual results, unless required by law.     
         

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD20(R);
HuMax-EGFr(TM);
HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM);
HuMax-CD32b(TM);  
HuMax-TF(TM); HuMax-Her2(TM); HuMax-VEGF(TM) and UniBody(R)
are all trademarks  
of Genmab A/S. Arzerra(TM) is a trademark of
GlaxoSmithKline.                   

Contact: Helle Husted, Vice President,
Investor Relations, T: +45 33 44 77 30,  
M: +45 25 27 47 13, E:
h.husted@genmab.com                                      
                    
                                                           
Stock Exchange
Release no. 46/2009                                              

###